A new model for post-integration latency in macroglial cells to study HIV-1 reservoirs of the brain

AIDS

Volumn 29, Issue 10, 2015, Pages 1147-1159

  Schneider, Martha ^a   Tigges, Bianca ^a   Meggendorfer, Manja ^a   Helfer, Markus ^a   Ziegenhain, Christoph ^a   Brack Werner, Ruth ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Activation; Brain; Functional cure; HIV 1 latency; Macroglia; Reservoirs; Suberoylanilide hydroxamic acid; TNF alpha

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PYRROLIDINE DITHIOCARBAMATE; TUMOR NECROSIS FACTOR ALPHA; VORINOSTAT; WITHAFERIN A; GREEN FLUORESCENT PROTEIN; VIRUS DNA; VIRUS RNA;

ARTICLE; BRAIN CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INVESTIGATIVE PROCEDURES; LATENT PERIOD; MACROGLIA; NEURAL STEM CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS EXPRESSION; VIRUS REACTIVATION; BIOLOGICAL MODEL; CELL CULTURE; GENETICS; GLIA; PHYSIOLOGY; PROVIRUS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; VIROLOGY; VIRUS DNA CELL DNA INTERACTION; VIRUS LATENCY;

CELLS, CULTURED; DNA, VIRAL; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HIV-1; HUMANS; MICROSCOPY, CONFOCAL; MODELS, BIOLOGICAL; NEURAL STEM CELLS; NEUROGLIA; PROVIRUSES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRUS INTEGRATION; VIRUS LATENCY;

EID: 84942889079     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000691     Document Type: Article

References (61)

1. Buzon MJ, Martin-Gayo E, Pereyra F, Ouyang Z, Sun H, Li JZ, et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol 2014; 88:10056-10065.
2. Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 2014; 512:74-77.
3. van der Sluis RM, van Montfort T, Pollakis G, Sanders RW, Speijer D, Berkhout B, et al. Dendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytes. PLoS Pathog 2013; 9:e1003259.
4. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Ann Rev Med 2002; 53:557-593.
5. McNamara LA, Ganesh JA, Collins KL. Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-(B activation. J Virol 2012; 86:9337-9350.
6. Buckner CM, Luers AJ, Calderon TM, Eugenin EA, Berman JW. Neuroimmunity and the blood-brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on neuroAIDS. J Neuroimmune Pharmacol 2006; 1:160-181.
7. Williams DW, Veenstra M, Gaskill PJ, Morgello S, Calderon TM, Berman JW. Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders. Curr HIV Res 2014; 12:85-96.
8. González-Scarano F, Martín-Garcá J. The neuropathogenesis of AIDS. Nature Rev Immunol 2005; 5:69-81.
9. Nath A. Eradication of human immunodeficiency virus from brain reservoirs. J Neurovirol 2014. Epub November 2014.
10. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-Associated neurocognitive disorders: mind the gap. Ann Neurol 2010; 67:699-714.
11. Churchill MJ, Wesselingh SL, Cowley D, Pardo CA, McArthur JC, Brew BJ, et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-Associated dementia. Annals Neurol 2009; 66:253-258.
12. Gray LR, Roche M, Flynn JK, Wesselingh SL, Gorry PR, Churchill MJ. Is the central nervous system a reservoir of HIV-1? Curr Opin HIV AIDS 2014; 9:552-558.
13. Kramer-Hämmerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res 2005; 111:194-213.
14. Schwartz L, Civitello L, Dunn-Pirio A, Ryschkewitsch S, Berry E, Cavert W, et al. Evidence of human immunodeficiency virus type 1 infection of nestin-positive neural progenitors in archival pediatric brain tissue. J Neurovirol 2007; 13:274-283.
15. Azevedo FA, Carvalho LR, Grinberg LT, Farfel JM, Ferretti RE, Leite RE, et al. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J Comp Neurol 2009; 513:532-541.
16. Pelvig D, Pakkenberg H, Stark A, Pakkenberg B. Neocortical glial cell numbers in human brains. Neurobiol Aging 2008; 29:1754-1762.
17. Overholser ED, Coleman GD, Bennett JL, Casaday RJ, Zink MC, Barber SA, et al. Expression of simian immunodeficiency virus (SIV) nef in astrocytes during acute and terminal infection and requirement of nef for optimal replication of neurovirulent SIV in vitro. J Virol 2003; 77:6855-6866.
18. Lawrence DM, Durham LC, Schwartz L, Seth P, Maric D, Major EO. Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells. J Virol 2004; 78:7319-7328.
19. Rothenaigner I, Kramer S, Ziegler M, Wolff H, Kleinschmidt A, Brack-Werner R. Long-term HIV-1 infection of neural progenitor populations. AIDS 2007; 21:2271-2281.
20. Narasipura SD, Kim S, Al-Harthi L. Epigenetic regulation of HIV-1 latency in astrocytes. J Virol 2014; 88:3031-3038.
21. Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013; 381:2109-2117.
22. Shan L, Siliciano RF. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication. Bioessays 2013; 35:544-552.
23. Nath A, Clements JE. Eradication of HIV from the brain: reasons for pause. AIDS (London, England) 2011; 25:577-580.
24. Manja Meggendorfer IR, Tigges B, Vincendeau M, Brack-Werner R. Neurotoxicity of HIV-1 proteins. In The neurology of AIDS. New York: Oxford University Press; 2012. pp. 275-288.
25. Zhou L, Saksena NK. HIV associated neurocognitive disorders. Infect Dis Rep 2013:5. eCollection.
26. Tan IL, McArthur JC. HIV-Associated neurological disorders. CNS Drugs 2012; 26:123-134.
27. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 2003; 22:1868-1877.
28. Shishido T, Wolschendorf F, Duverger A, Wagner F, Kappes J, Jones J, et al. Selected drugs with reported secondary celldifferentiating capacity prime latent HIV-1 infection for reactivation. J Virol 2012; 86:9055-9069.
29. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4R T cells from aviremic patients. PLoS Pathog 2013; 9:e1003834.
30. Xing S, Siliciano RF. Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today 2013; 18:541-551.
31. Van Lint C, Bouchat S, Marcello A. HIV-1 transcription and latency: an update. Retrovirology 2013; 10:67.
32. Wires ES, Alvarez D, Dobrowolski C, Wang Y, Morales M, Karn J, et al. Methamphetamine activates nuclear factor kappa-lightchain-enhancer of activated B cells (NF-kB) and induces human immunodeficiency virus (HIV) transcription in human microglial cells. J Neurovirol 2012; 18:400-410.
33. Rothenaigner I, Kramer S, Meggendorfer M, Rethwilm A, Brack-Werner R. Transduction of human neural progenitor cells with foamy virus vectors for differentiation-dependent gene expression. Gene Ther 2008; 16:349-358.
34. Rubio FJ, Bueno C, Villa A, Navarro B, Martnez-Serrano A. Genetically perpetuated human neural stem cells engraft and differentiate into the adult mammalian brain. Mol Cell Neurosci 2000; 16:1-13.
35. Villa A, Snyder EY, Vescovi A, Martnez-Serrano A. Establishment and properties of a growth factor-dependent, perpetual neural stem cell line from the human CNS. Exp Neurol 2000; 161:67-84.
36. Kremb S, Helfer M, Heller W, Hoffmann D, Wolff H, Kleinschmidt A, et al. EASY-HIT: HIV full-replication technology for broad discovery of multiple classes of HIV inhibitors. Antimicrob Agents Chemother 2010; 54:5257-5268.
37. Geeraert L, Kraus G, Pomerantz RJ. Hide-And-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 2008; 59:487-501.
38. Williams SA, Greene WC. Regulation of HIV-1 latency by T-cell activation. Cytokine 2007; 39:63-74.
39. Bartholomeeusen K, Fujinaga K, Xiang Y, Peterlin BM. Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J Biol Chem 2013; 288:14400-14407.
40. Ramakrishnan R, Liu H, Rice AP. SAHA (Vorinostat) induces CDK9 Thr-186 (T-Loop) phosphorylation in resting CD4R T cells: implications for reactivation of latent HIV. AIDS Res Hum Retrovirus 2014.
41. Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Exp Opin Investig Drugs 2013; 22:723-738.
42. Canduri F, Peres PC, Caceres RA, de Azevedo J, Filgueira W. CDK9 a potential target for drug development. Med Chem 2008; 4:210-218.
43. Wesierska-Gadek J, Maurer M, Zulehner N, Komina O. Whether to target single or multiple CDKs for therapy? That is the question. J Cell Physiol 2011; 226:341-349.
44. Mohammadi P, CiuffiA, Beerenwinkel N. Dynamic models of viral replication and latency. Curr Opin HIV AIDS 2015; 10:90-95.
45. Chaboub LS, Deneen B. Developmental origins of astrocyte heterogeneity: the final frontier of CNS development. Dev Neurosci 2012; 34:379-388.
46. Dimou L, Götz M. Glial cells as progenitors and stem cells: new roles in the healthy and diseased brain. Physiol Rev 2014; 94:709-737.
47. Guérout N, Li X, Barnabé-Heider F. Cell fate control in the developing central nervous system. Exp Cell Res 2014; 321:77-83.
48. Abdulle S, MellgrenA , Brew BJ, Cinque P, Hagberg L, Price RW, et al. CSF neurofilament protein (NFL): a marker of active HIV-related neurodegeneration. J Neurol 2007; 254:1026-1032.
49. Keating SM, Jacobs ES, Norris PJ. Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development. Cytokine Growth Factor Rev 2012; 23:193-206.
50. Kraft-Terry SD, Buch SJ, Fox HS, Gendelman HE. A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron 2009; 64:133-145.
51. Archin N, Liberty A, Kashuba A, Choudhary S, Kuruc J, Hudgens M, et al. Administration of vorinostat disrupts HIV-1 latency in patients on ART. In 18th Annual Conference on Retroviruses and Opportunistic Infections; 2012.
52. Del Prete GQ, Shoemaker R, Oswald K, Lara A, Trubey CM, Fast R, et al. Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected Indian rhesus macaques. Antimicrob Agents Chemother 2014; 58:6790-6806.
53. Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E, et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 2009; 15:6148-6157.
54. Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak M, Coffin JM, et al. Quantification of HIV-1 latency reversal in resting CD4R T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci 2014; 111:7078-7083.
55. Wightman F, Ellenberg P, Churchill M, Lewin SR. HDAC inhibitors in HIV. Immunol Cell Biol 2011; 90:47-54.
56. Rice AP, Herrmann CH. Regulation of TAK/P-TEFb in CD4R T lymphocytes and macrophages. Curr HIV Res 2003; 1:395-404.
57. Bisgrove DA, Mahmoudi T, Henklein P, Verdin E. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc Natl Acad Sci 2007; 104:13690-13695.
58. Zhang Z, Klatt A, Gilmour DS, Henderson AJ. Negative elongation factor NELF represses human immunodeficiency virus transcription by pausing the RNA polymerase II complex. J Biol Chem 2007; 282:16981-16988.
59. Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 2011; 12:471-480.
60. Chao S-H, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000; 275:28345-28348.
61. Yu L, Mohanram V, Simonson OE, Smith C, Spetz A-L, Mohamed AJ. Proteasome inhibitors block HIV-1 replication by affecting both cellular and viral targets. Biochem Biophys Res Commun 2009; 385:100-105.